Entheon Biomedical Corp Stock Performance
| ENTBF Stock | USD 0.12 0.03 33.33% |
Entheon Biomedical holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 2.37, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Entheon Biomedical will likely underperform. Use Entheon Biomedical treynor ratio, expected short fall, day typical price, as well as the relationship between the potential upside and daily balance of power , to analyze future returns on Entheon Biomedical.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Entheon Biomedical Corp are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak fundamental drivers, Entheon Biomedical reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.8 M | |
| Total Cashflows From Investing Activities | -98.9 K |
Entheon |
Entheon Biomedical Relative Risk vs. Return Landscape
If you would invest 10.00 in Entheon Biomedical Corp on September 17, 2024 and sell it today you would earn a total of 2.00 from holding Entheon Biomedical Corp or generate 20.0% return on investment over 90 days. Entheon Biomedical Corp is currently producing 4.4084% returns and takes up 35.3224% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Entheon, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Entheon Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Entheon Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Entheon Biomedical Corp, and traders can use it to determine the average amount a Entheon Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1248
| Best Portfolio | Best Equity | ENTBF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 35.32 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.41 actual daily | 88 88% of assets have lower returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Entheon Biomedical is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Entheon Biomedical by adding it to a well-diversified portfolio.
Entheon Biomedical Fundamentals Growth
Entheon OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Entheon Biomedical, and Entheon Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Entheon OTC Stock performance.
| Return On Equity | -0.55 | |||
| Return On Asset | -0.46 | |||
| Operating Margin | (60.27) % | |||
| Current Valuation | 1.12 M | |||
| Shares Outstanding | 59.09 M | |||
| Price To Book | 0.22 X | |||
| Price To Sales | 9.60 X | |||
| Revenue | 21.67 K | |||
| EBITDA | (8.62 M) | |||
| Cash And Equivalents | 467.58 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 300 K | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | 0.11 X | |||
| Cash Flow From Operations | (5.62 M) | |||
| Earnings Per Share | (0.11) X | |||
| Total Asset | 9.98 M | |||
About Entheon Biomedical Performance
By analyzing Entheon Biomedical's fundamental ratios, stakeholders can gain valuable insights into Entheon Biomedical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Entheon Biomedical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Entheon Biomedical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. Entheon Biomedical Corp. is headquartered in Vancouver, Canada. ENTHEON BIOMEDICAL operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about Entheon Biomedical Corp performance evaluation
Checking the ongoing alerts about Entheon Biomedical for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Entheon Biomedical Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Entheon Biomedical is way too risky over 90 days horizon | |
| Entheon Biomedical has some characteristics of a very speculative penny stock | |
| Entheon Biomedical appears to be risky and price may revert if volatility continues | |
| Entheon Biomedical Corp has accumulated 300 K in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Entheon Biomedical Corp has a current ratio of 0.95, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Entheon Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, Entheon Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Entheon Biomedical Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Entheon to invest in growth at high rates of return. When we think about Entheon Biomedical's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 21.67 K. Net Loss for the year was (8.89 M) with profit before overhead, payroll, taxes, and interest of 9.13 K. | |
| Entheon Biomedical Corp has accumulated about 467.58 K in cash with (5.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
- Analyzing Entheon Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Entheon Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining Entheon Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Entheon Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Entheon Biomedical's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Entheon Biomedical's otc stock. These opinions can provide insight into Entheon Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Entheon OTC Stock analysis
When running Entheon Biomedical's price analysis, check to measure Entheon Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entheon Biomedical is operating at the current time. Most of Entheon Biomedical's value examination focuses on studying past and present price action to predict the probability of Entheon Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entheon Biomedical's price. Additionally, you may evaluate how the addition of Entheon Biomedical to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |